Veracyte (VCYT) Current Deferred Revenue (2012 - 2026)

Veracyte (VCYT) has 13 years of Current Deferred Revenue data on file, last reported at $749000.0 in Q1 2026.

• Quarterly Current Deferred Revenue fell 56.25% year-over-year to $749000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $749000.0 (down 56.25% YoY) and the FY2025 annual result came in at $1.2 million, down 30.66% from the prior year.
• Current Deferred Revenue slipped to $749000.0 in Q1 2026 per VCYT's latest filing, from $1.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $4.9 million in Q1 2022, with the low at $417000.0 in Q3 2025.
• Average Current Deferred Revenue over 5 years is $2.3 million, with a median of $2.2 million recorded in 2023.
• Year-over-year, Current Deferred Revenue surged 974.45% in 2022 and plunged 79.49% in 2025.
• Veracyte's Current Deferred Revenue stood at $2.6 million in 2022, then fell by 23.15% to $2.0 million in 2023, then decreased by 16.68% to $1.7 million in 2024, then sank by 30.66% to $1.2 million in 2025, then plunged by 35.43% to $749000.0 in 2026.
• Business Quant data shows VCYT's Current Deferred Revenue at $749000.0 in Q1 2026, $1.2 million in Q4 2025, and $417000.0 in Q3 2025.